deltatrials
Completed PHASE2 INTERVENTIONAL NCT00005938

DX-8951f in Treating Patients With Biliary Cancer

A Phase II Study of Intravenous DX-8951f Administered Daily for Five Days Every Three Weeks to Patients With Biliary Tree Cancer (Cholangiocarcinoma and Gallbladder Cancer)

Sponsor: Daiichi Sankyo

Conditions Extrahepatic Bile Duct Cancer Gallbladder Cancer Liver Cancer
Interventions exatecan mesylate
Updated 8 times since 2017 Last updated: May 15, 2012 Started: Mar 31, 2000 Primary completion: Apr 30, 2005 Completion: Apr 30, 2005
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Extrahepatic Bile Duct Cancer and Gallbladder Cancer, this trial is completed. The trial is conducted by Daiichi Sankyo and has accumulated 8 data snapshots since 2000. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshotCompleted~Feb 2017 – ~Sep 2017 · 7 months · monthly snapshotCompleted~Sep 2017 – ~Jun 2018 · 9 months · monthly snapshotCompleted~Jun 2018 – ~Jan 2021 · 31 months · monthly snapshotCompleted~Jan 2021 – ~Mar 2024 · 38 months · monthly snapshotCompleted~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 21 months · monthly snapshotCompleted

Change History

8 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Mar 2024 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jan 2021 — Mar 2024 [monthly]

    Completed PHASE2

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE2

▶ Show 3 earlier versions

  1. Sep 2017 — Jun 2018 [monthly]

    Completed PHASE2

  2. Feb 2017 — Sep 2017 [monthly]

    Completed PHASE2

  3. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE2

    First recorded

Mar 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Daiichi Sankyo
Data source: Daiichi Sankyo

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations